OSTEOVISION DIN 02462141
Status: Dormant
Holder: CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION
Molecule: SODIUM FLUORIDE F
Health Canada record
| Active ingredient(s) | SODIUM FLUORIDE F 18 11.1 GBQ |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | SCHEDULE C |
| Class | Radiopharmaceutical |
| ATC | V09IX06 SODIUM FLUORIDE (18F) |
| Original market date | 31-Jan-2019 |
| Current status date | 29-Jul-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Centre for Probe Development and Commercialization — licence 101848, not currently licensed, last inspection rating C (2022-05-30).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SODIUM FLUORIDE F
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02402017 | NAF PLUS | ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS LTD. | Solution | SODIUM FLUORIDE F 18 7400 MBq | Marketed |
International API supply for SODIUM FLUORIDE F
0 active FDA Drug Master Files.
Request a quote for OSTEOVISION